SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.85-4.5%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (10642)2/26/2004 1:00:17 PM
From: Harold Engstrom  Read Replies (2) of 52153
 
Creative Biomolecules... I remember those days: Stryker bought some of the company and the R&D part became Curis. I did some work at the old CBMI in Hopkinton,MA and New Lebanon, NH.

Have always been skeptical of their ability to deliver. Nothing came out of the investment that Biogen made (that I know of), nothing has come out of Elan's investment (that I know of), and the compound CBMI and BGEN collaborated on for treatment of renal failure had soluability issues. What has CBMI succeeded with?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News